Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jane B. Vaselkiv"'
Autor:
Hari S Iyer, Jane B Vaselkiv, Konrad H Stopsack, Charlotte J Roscoe, Nicole V DeVille, Yiwen Zhang, Kathryn L Penney, Steven P Balk, Michelangelo Fiorentino, Jaime E Hart, Peter James, Immaculata De Vivo, Lorelei A Mucci, Francine Laden, Timothy R Rebbeck
Publikováno v:
American Journal of Epidemiology.
Adverse neighborhood social and natural (greenspace) environments may contribute to prostate cancer (CaP) etiology, but mechanisms are unclear. We examined associations between neighborhood environment and prostate intratumoral inflammation in 967 me
Autor:
Megan Hansen, Nadine M. Hamieh, Sarah C. Markt, Jane B. Vaselkiv, Claire H. Pernar, Amparo G. Gonzalez-Feliciano, Samuel Peisch, Ilkania M. Chowdhury-Paulino, Emily M. Rencsok, Timothy R. Rebbeck, Elizabeth A. Platz, Edward L. Giovannucci, Kathryn M. Wilson, Lorelei A. Mucci
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background: Racial disparities in prostate cancer incidence and mortality rates are considerable. We previously found in the Health Professionals Follow-up Study (HPFS) that African-American men had an 80% higher prostate cancer risk than White men.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26bc80bf595d7bf8b6017cf234ca4944
https://europepmc.org/articles/PMC9083301/
https://europepmc.org/articles/PMC9083301/
Autor:
Naiyu Chen, Colleen B. McGrath, Caroline I. Ericsson, Jane B. Vaselkiv, Michelle O. Sodipo, Emily M. Rencsok, Konrad H. Stopsack, Daniel J. George, Karen A. Autio, Dana E. Rathkopf, Kathryn L. Penney, Lorelei A. Mucci
Publikováno v:
Cancer Research. 83:6489-6489
Background: More than 100,000 individuals in the United States are survivors of advanced prostate cancer, defined as metastatic hormone sensitive (mHSPC) or castration resistant prostate cancer (CRPC). This growing, vulnerable population could be uni
Autor:
Zhike Lin, Konrad H. Stopsack, Michelangelo Fiorentino, Jane B. Vaselkiv, Travis Gerke, Andreas Pettersson, Sinead Flanagan, Kathryn L. Penney, Stephen P. Finn, Massimo Loda, Lorelei A. Mucci
Publikováno v:
Cancer Research. 83:737-737
Background: Gleason score is one of the strongest prognostic factors for prostate cancer survival in patients with primary prostate cancer. However, its predictive accuracy is less clear during extended follow-up periods. Methods: We included men dia
Autor:
Qinran Liu, Yiwen Zhang, Jane B. Vaselkiv, Lorelei A. Mucci, Edward L. Giovannucci, Elizabeth A. Platz, Siobhan Sutcliffe
Publikováno v:
Cancer Research. 83:4203-4203
Introduction: Birth weight, a potential marker of the in utero hormonal and growth factor milieu, has been associated with an increased risk of prostate cancer (PCa) in some, but not all, previous studies. It was also associated with a non-significan
Autor:
Jane B. Vaselkiv, Carl Ceraolo, Kathryn M. Wilson, Claire H. Pernar, Emily M. Rencsok, Konrad H. Stopsack, Sydney T. Grob, Anna Plym, Edward L. Giovannucci, Aria F. Olumi, Adam S. Kibel, Mark A. Preston, Lorelei A. Mucci
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 31(7)
Background: How 5-alpha reductase inhibitor (5-ARI) use influences prostate cancer mortality is unclear. The objective of this study was to determine whether men taking 5-ARIs with regular health care access have increased prostate cancer mortality.
Autor:
Jane B. Vaselkiv, Iona Cheng, Ilkania M. Chowdhury-Paulino, Amparo G. Gonzalez-Feliciano, Lynne R. Wilkens, Alda M. Hauksdóttir, Gudny Eiriksdottir, Loïc Le Marchand, Christopher A. Haiman, Unnur Valdimarsdóttir, Lorelei A. Mucci, Sarah C. Markt
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background: The circadian hormone melatonin has anticancer properties, and prior studies suggest a positive association between low melatonin and prostate cancer risk. The purpose of this study was to examine urinary melatonin levels and prostate can